Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Regeneron Pharmaceuticals Inc — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B), while Regeneron Pharmaceuticals Inc trades at $746.54 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 6.1× Halozyme Therapeutics Inc. Common Stock's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| HALO | REGN | |
|---|---|---|
Market Cap | $12.58B | $76.14B |
Volume | 2,179,278 | 500,239 |
Sector | Health | Health |
52-Week High | $115.22 | $852.03 |
52-Week Low | $61.63 | $557.73 |
Typical Hold Time | 1 Days | 107 Days |
Enterprise Value | $14.49B | $70.85B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Regeneron Pharmaceuticals (REGN) trades at $746.54, up 0.6% on the day, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments. Cash flow improved in 2025, and profitability remains robust with a net income margin of 27.86%.
The outlook is positive, driven by the expanded Sanofi partnership and promising clinical trial updates, though technical indicators suggest near-term resistance. Risks include competitive pressures in key drug markets and reliance on successful drug development. Analysts are bullish with a consensus price target of $849.84, indicating potential upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
